ERBB2 and breast cancer: Liquid biopsy represents a tool that could potentially be used to obtain the complete molecular picture of a tumour, including HER2-positive BC, and perform treatment response monitoring, pathological complete response (pCR) and outcome prediction and/or screening for early tumour identification in asymptomatic individuals [25].